Resurgence of Polymyxin B for MDR/XDR Gram-Negative Infections: An Overview of Current Evidence

<div>Bactericidal activity of all monotherapy and polymyxin B combination treatments in XDR<i> A. baumannii </i>[<a href="/journals/ccrp/2017/3635609/#B44">44</a>].</div>

Critical Care Research and Practice

fig2

Figure 2

Figure 2: Resurgence of Polymyxin B for MDR/XDR Gram-Negative Infections: An Overview of Current Evidence 